 To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c 7 at the end of the treatment period and do not experience symptomatic hypoglycemia, confirmed by plasma glucose PG 56 mgdL 3.1 mmolL 